As TruScreen’s results come from an objective, self-checking digital system, they are free of the highly subjective human judgment required for cellular diagnosis on conventional screening methods, such as Pap Smears.
TruScreen can be effectively used with minimal training of medical, or paramedical staff, to allow cervical cancer detection without the infrastructure and resource costs associated with conventional, cytology-based screening. TruScreen is also more acceptable to women than a conventional Pap test.
The TruScreen device has been clinically validated, with large clinical studies including over 20,000 women in multiple settings.*Frequently Asked Questions
TruScreen offers an alternative approach to cervical screening, resolving manty of the ongoing issues with conventional screening methods including failed samples, poor patient follow up, patient discomfort and the need for supporting laboratory infrastructure.
As TruScreen’s results come from an objective, self-checking, AI-enabled system, they are free from the highly subjective human judgement that conventional screening methods are so reliant on. The TruScreen device has been clinically validated, with large clinical studies including over 20,000 women in multiple settings.*
TruScreen can be effectively used with minimal training to allow for cervical cancer screening without the infrastructure and resource costs associated with conventional, cytology based screening.
As a vast majority of clinical evaluations and trials are conducted in our key markets, there is a large volume of papers that are only available in the native language of the publication’s region.
Below are some English published papers on TruScreen that are available in the public domain.
CHINA | 458 patients
CHINA | 9,972 PATIENTS
CHINA | 1,344 PATIENTS
CHINA | META-ANALYSIS | 2,730 PATIENTS
POLAND | 293 PATIENTS
KOREA | 292 PATIENTS
CHINA | 487 PATIENTS
POLAND | 147 PATIENTS
Pioneering research and development on the TruScreen cervical cancer screening system for real-time cervical tissue differentiation has involved close collaboration with leading clinicians and hospitals across the world.Development History
TruScreen is a real-time, objective screening device. It is CE certified as a primary screening tool. TruScreen screens for the presence of pre-cancerous and cancerous tissue in the cervix.TruScreen Device Overview
*Total number of subjects across published clinical studies in English, data from TruScreen device generation I and II. Reference: Data on File, December 2020